We are live on ! Find out more
WHWK

Whitehawk Therapeutics

68 hedge funds and large institutions have $159M invested in Whitehawk Therapeutics in 2022 Q2 according to their latest regulatory filings, with 23 funds opening new positions, 15 increasing their positions, 19 reducing their positions, and 10 closing their positions.

New
Increased
Maintained
Reduced
Closed

130% more first-time investments, than exits

New positions opened: 23 | Existing positions closed: 10

24% more funds holding

Funds holding: 5568 (+13)

2.36% more ownership

Funds ownership: 60.85%63.21% (+2.4%)

21% less repeat investments, than reductions

Existing positions increased: 15 | Existing positions reduced: 19

25% less funds holding in top 10

Funds holding in top 10: 43 (-1)

27% less capital invested

Capital invested by funds: $219M → $159M (-$59.9M)

Holders
68
Holders Change
+13
Holders Change %
+23.64%
% of All Funds
1.15%
Holding in Top 10
3
Holding in Top 10 Change
-1
Holding in Top 10 Change %
-25%
% of All Funds
0.05%
New
23
Increased
15
Reduced
19
Closed
10
Calls
$2.79M
Puts
Net Calls
+$2.79M
Net Calls Change
+$940K
Name Holding Trade Value Shares
Change
Change in
Stake
ACA
1
Avoro Capital Advisors
New York
$22.5M
ACP
2
Acuta Capital Partners
California
$18.8M
VA
3
VR Adviser
New York
$14.5M -$5.29M -355,884 -23%
BlackRock
4
BlackRock
New York
$11.1M +$8.8M +592,550 +191%
BI
5
BVF Inc
California
$10.8M
Vanguard Group
6
Vanguard Group
Pennsylvania
$10.3M +$1.09M +73,544 +10%
RI
7
RTW Investments
New York
$9.42M
Point72 Asset Management
8
Point72 Asset Management
Connecticut
$6.68M +$4.91M +330,513 +156%
State Street
9
State Street
Massachusetts
$6.6M +$535 +36 +0%
DCMIC
10
Decheng Capital Management III (Cayman)
Cayman Islands
$6.48M
VC
11
Vivo Capital
California
$6.28M -$3.9M -262,844 -34%
RCM
12
RA Capital Management
Massachusetts
$4.72M +$5.69M +383,028 New
AIM
13
Alerce Investment Management
Illinois
$4.62M
Geode Capital Management
14
Geode Capital Management
Massachusetts
$3.84M +$1.7M +114,533 +58%
T. Rowe Price Associates
15
T. Rowe Price Associates
Maryland
$3.05M -$2.8M -188,713 -43%
Citadel Advisors
16
Citadel Advisors
Florida
$2.87M -$18.7K -1,256 -0.5%
Renaissance Technologies
17
Renaissance Technologies
New York
$2.14M +$505K +34,000 +24%
GTC
18
Ghost Tree Capital
New York
$1.85M
Northern Trust
19
Northern Trust
Illinois
$1.65M +$1.46M +97,966 +270%
IC
20
Ikarian Capital
Texas
$1.27M +$3.03M +203,975 +98%
EP
21
Eversept Partners
New York
$1.24M -$743K -50,000 -33%
HF
22
HRT Financial
New York
$642K +$774K +52,122 New
Goldman Sachs
23
Goldman Sachs
New York
$538K -$236K -15,885 -27%
Bank of New York Mellon
24
Bank of New York Mellon
New York
$517K +$456K +30,679 +271%
ECM
25
ExodusPoint Capital Management
New York
$507K -$40.2K -2,706 -6%

WHWK Hedge Fund Activity: Q2 2022 in Review

68 of the 5,936 institutional investors tracked by Wall St. Rank reported a position in Whitehawk Therapeutics (WHWK) for Q2 2022, worth a combined $159M — down 27% from $219M a quarter earlier.

Buyers outnumbered sellers: 23 funds opened new WHWK positions and 10 closed out — a net gain of 13 holders — while 15 added to existing stakes and 19 trimmed.

The largest buyer was BlackRock, adding an estimated $8.8M. The largest seller was RK Capital Management (Colorado), exiting entirely with an estimated $5.36M sold.

  • 68 institutional investors held Whitehawk Therapeutics (WHWK) as of Q2 2022, up from 55 in Q1 2022.
  • Funds reported $159M of Whitehawk Therapeutics stock for Q2 2022, down 27% quarter-over-quarter.
  • 23 funds opened new Whitehawk Therapeutics positions in Q2 2022 and 10 closed out, a net change of +13 holders.
  • The largest Whitehawk Therapeutics buyer in Q2 2022 was BlackRock, an estimated $8.8M added.
  • The largest Whitehawk Therapeutics seller in Q2 2022 was RK Capital Management (Colorado), an estimated $5.36M sold.

Based on aggregated 13F filings for Q2 2022.